<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Health Sci J</journal-id><journal-id journal-id-type="iso-abbrev">Curr Health Sci J</journal-id><journal-id journal-id-type="publisher-id">CHSJ</journal-id><journal-title-group><journal-title>Current Health Sciences Journal</journal-title></journal-title-group><issn pub-type="ppub">2067-0656</issn><issn pub-type="epub">2069-4032</issn><publisher><publisher-name>Medical University Publishing House Craiova</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25729603</article-id><article-id pub-id-type="pmc">4340438</article-id><article-id pub-id-type="publisher-id">2014.3.05</article-id><article-id pub-id-type="doi">10.12865/CHSJ.40.03.05</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>The Expression of Twist in Differentiated Thyroid Carcinomas</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>CALANGIU</surname><given-names>CRISTINA MARIANA</given-names></name><xref ref-type="aff" rid="AFF1">1</xref></contrib><contrib contrib-type="author"><name><surname>M&#x00102;RG&#x00102;RITESCU</surname><given-names>C.</given-names></name><xref ref-type="aff" rid="AFF2">2</xref></contrib><contrib contrib-type="author"><name><surname>CERNEA</surname><given-names>DANIELA</given-names></name><xref ref-type="aff" rid="AFF3">3</xref></contrib><contrib contrib-type="author"><name><surname>STEPAN</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="AFF2">2</xref></contrib><contrib contrib-type="author"><name><surname>SIMIONESCU</surname><given-names>CRISTIANA EUGENIA</given-names></name><xref ref-type="aff" rid="AFF2">2</xref></contrib></contrib-group><aff id="AFF1"><label>1</label>Phd Student, Pathology Department, University of Medicine and Pharmacy of Craiova</aff><aff id="AFF2"><label>2</label>Pathology Department, University of Medicine and Pharmacy of Craiova</aff><aff id="AFF3"><label>3</label>Department of Care and Anesthesiology, University of Medicine and Pharmacy of Craiova</aff><author-notes><corresp id="cor1">Corresponding Author: Alex Stepan, Assistant, MD, PhD
<named-content content-type="dept">Department of Pathology </named-content><institution>University of Medicine and Pharmacy of Craiova</institution><addr-line>66, 1 May Avenue</addr-line><addr-line>Craiova 200628</addr-line><country>Romania</country><email>astepan76@yahoo.com</email><phone>+40251&#x02013;599 228</phone></corresp></author-notes><pub-date pub-type="ppub"><season>Jul-Sep</season><year>2014</year></pub-date><pub-date pub-type="epub"><day>04</day><month>8</month><year>2014</year></pub-date><volume>40</volume><issue>3</issue><fpage>184</fpage><lpage>189</lpage><history><date date-type="received"><day>27</day><month>1</month><year>2014</year></date><date date-type="accepted"><day>10</day><month>6</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014, Medical University Publishing House Craiova</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0/"><license-p>This is an open-access article distributed under the terms of a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International Public License, which permits unrestricted use, adaptation, distribution and reproduction in any medium, non-commercially, provided the new creations are licensed under identical terms as the original work and the original work is properly cited.</license-p></license></permissions><abstract><p>Differentiated thyroid carcinoma are lesions with a generally favorable prognosis, although there are patients with risk of recurrence and metastasis. In this study we analyzed 43 thyroid carcinomas referring to Twist expression in relation to clinicopathological parameters. The immunoreaction was identified in 79% of cases, the expression of twist being low or high, with no differences in relation to the tumors type or subtype. Twist immunoexpression differ depending on tumor stage and presence of metastases, the immunostain being significantly higher in invasive tumors to adjacent structures and in cases of tumors with metastasized. In differentiated thyroid carcinomas overexpression of Twist is associated with an invasive and metastatic immunophenotype.</p></abstract><kwd-group kwd-group-type="author"><kwd>thyroid carcinomas</kwd><kwd>TWIST</kwd><kwd>immunoexpression</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>In the last two decades there have been progresses in understanding thyroid carcinoma histogenesis and biology. Papillary thyroid carcinomas (PTC) represents 80% of thyroid malignancies and is characterized by slow growth and an excellent prognosis [<xref rid="B1" ref-type="bibr">1</xref>]. Patients with PTC have the best survival rate of all types of thyroid cancer, with a ten-year rate to 95% [<xref rid="B2" ref-type="bibr">2</xref>], or by other studies 5-year survival is 96% and in 10 years 93 % [<xref rid="B3" ref-type="bibr">3</xref>]. Differentiated follicular thyroid carcinoma (FTC) constitute 10-17% of malignant thyroid pathology and also have a good long-term prognosis [<xref rid="B4" ref-type="bibr">4</xref>]. However, some cases have relatively early relapses, invasion of adjacent structures, lymph node metastases or distant metastases [<xref rid="B5" ref-type="bibr">5</xref>].</p><p>Thyroid carcinoma that invade local structures are associated with poor prognosis, but the invasion mechanisms are incompletely defined, limiting the development of new therapies. Understanding the molecular mechanisms involved in the progression of thyroid cancer may provide targets for more effective treatment in aggressive thyroid cancer.</p><p>Twist is considered to have oncogenic potential by promoting the proliferation and inhibition of apoptosis [<xref rid="B6" ref-type="bibr">6</xref>]. It acts in cooperation with Bmi1 inhibiting the expression of epithelial markers such as E-cadherin, and is associated with poor prognosis in a variety of cancers of the head and neck [<xref rid="B7" ref-type="bibr">7</xref>]. Loss of E-cadherin expression, in turn leads to loss of cell adhesion and polarity and acquisition of migratory and invasive phenotype of epithelial cells [<xref rid="B8" ref-type="bibr">8</xref>].</p><p>In this study we aimed the analysis of Twist expression in differentiated thyroid carcinomas and the correlation with clinical and morphological parameters.</p></sec><sec><title>Matherial and Method</title><p>The study included a total of 43 differentiated thyroid carcinomas selected in a period of nine years from patients hospitalized and operated in Surgery Clinics of Emergency County Hospital of Craiova. he surgical pieces were fixed in 10% buffered formalin, processed by the usual technique with paraffin embedding and Hematoxylin-Eosin stain. Classification of the tumors was made in accordance with literature data [<xref rid="B1" ref-type="bibr">1</xref>]. </p><p>Subsequently the specimens were processed by immunohistochemistry, using citrate antigen recovery buffer pH 6 and a peroxidase-based polymer secondary detection system (Histofine polymer-HRP, Nichirei, Japan, ready to use, code 414151F). The visualization of reactions was done with DAB chromogen (code 3467, Dako), and to validate the results were used positive (tonsil) and negative (omitting the primary antibody) external controls. The tissues analyzed were incubated overnight at 4&#x000b0; C with monoclonal mouse antibody antihuman Twist, diluted 1/2000 (LSBio, code LS-C191858)</p><p>We quantified semiquantitatively the expression of Twist by a scoring system which has been assigned two independent specialists on the basis of staining intensity and percentage of positive cells [<xref rid="B9" ref-type="bibr">9</xref>]. The intensity score was noted with 0 (no staining), 1 (low intensity), 2 (moderate intensity), and 3 (high intensity). The score of the percentage stained cells was noted with 0 (&#x0003c;5% positive cells), 1 (6-25% positive cells), 2 (26-50% positive cells), 3 (51-75% positive cells) , and 4 (&#x0003e; 75% positive cells). The multiplication of the intensity and percentage scores allowed the calculation of the composite final score: 0 (negative), + (1-4) + (5-8), and + + + (9-12). For the statistical analysis, a final staining score of negative or + was considered with low expression and a score of final staining + + or + + + correspond to the group with high expression. The statistical analysis was performed using automatically SPSS10 software and chi-square and Fisher's exact tests.
</p></sec><sec sec-type="results"><title>Results</title><p>Analysis of clinicopathological parameters of the 43 thyroid differentiated carcinomas indicated an upward trend since the third decade of life, the maximum incidence being after age 60 years, predominantly in females (Table <xref ref-type="table" rid="T1">1</xref>).</p><p>Histopathological analysis revealed that the most investigated PTC correspond to conventional type in 23 cases (59%), followed by follicular variant in 13 cases (33.3%), and tall cell variant in 3 cases (7.7%), while for FTC the conventional type was the most common, respectively in 3 cases (75%). The classification of lesions according to the TNM staging indicated 18 cases in stage I, 14 cases in stage II, 7 cases in stage III and 4 cases in stage IVA (Table <xref ref-type="table" rid="T1">1</xref>).</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>The clinicopathological analyzed parameters </p></caption><table frame="hsides" rules="groups" border="1"><tbody><tr><td colspan="2" align="center" rowspan="1">Tumor type/ Parameter</td><td align="center" rowspan="1" colspan="1">Conventional PTC </td><td align="center" rowspan="1" colspan="1">Follicular PTC</td><td align="center" rowspan="1" colspan="1">Tall cell variant PTC</td><td align="center" rowspan="1" colspan="1">Conventional FTC</td><td align="center" rowspan="1" colspan="1">Clear cell variant FTC</td></tr><tr><td rowspan="2" align="center" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">&#x0003c;45 years</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x0003e;45 years</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td rowspan="2" align="center" colspan="1">Gender</td><td align="center" rowspan="1" colspan="1">female</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="center" rowspan="1" colspan="1">male</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td rowspan="4" align="center" colspan="1">Stage</td><td align="center" rowspan="1" colspan="1">I</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1">II</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="center" rowspan="1" colspan="1">III</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1">IVA</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr></tbody></table></table-wrap><p>In 10 cases of PTC, we found the presence of lymph node metastases, from which 5 cases conventional type, 3 cases of follicular variant and 2 cases tall cell variant.</p><p>In the study the analysis of TWIST expression revealed positivity in 34 of the cases, the signal being cytoplasmic and nuclear (Table <xref ref-type="table" rid="T2">2</xref>). Nuclear or nuclear / cytoplasmic immunostain localization was present in 79% of cases, and negative in 21% of the cases. Because TWIST is a nuclear transcription factor, for the immunohistochemical analysis we considering only the nuclear signal.</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>The incidence of thyroid carcinomas expression by TWIST staining scores </p></caption><table frame="hsides" rules="groups" border="1"><tbody><tr><td rowspan="2" align="center" colspan="1">Histologic type/<break/>
Immunoreaction</td><td colspan="2" align="center" rowspan="1">low expression </td><td colspan="2" align="center" rowspan="1">high expression </td></tr><tr><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">+</td><td align="center" rowspan="1" colspan="1">++</td><td align="center" rowspan="1" colspan="1">+++</td></tr><tr><td align="center" rowspan="1" colspan="1">Conventional PTC</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">4</td></tr><tr><td align="center" rowspan="1" colspan="1">Follicular PTC</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="center" rowspan="1" colspan="1">Tall cell variant PTC</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="center" rowspan="1" colspan="1">Conventional FTC</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="center" rowspan="1" colspan="1">Clear cell variant FTC</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr></tbody></table></table-wrap><p>The evaluation of staining scores indicated for the majority of tumors values above 3. All variants of the PTC examined, except the tall cell variant, included cases with both low and high expression for TWIST (fig.<xref ref-type="fig" rid="F1">1</xref>). To note that the three cases of PTC tall cell variant presented high expression for TWIST.</p><p>Thus, in the conventional papillary carcinoma, the average score of positivity was 5.83, with mostly moderate / high intensity of reactions and a percentage of the marked cells of 20-80% (fig.<xref ref-type="fig" rid="F1">1</xref>A-B). Regarding follicular and tall cell variants of PTC, the positivity average score was 5.60, respectively 7.00, intensity mostly moderate / high and a percentage of labeled cells between 20-80% and respectively 50-70 % (fig.<xref ref-type="fig" rid="F1">1</xref>C-D). Comparative, FTC indicated a positivity score of 4.66, the reactions presenting moderate / high intensity, with a percentage of labeled cells of 25-65% (fig.<xref ref-type="fig" rid="F1">1</xref>E-F). </p><fig id="F1" orientation="portrait" position="float"><label>Fig.1</label><caption><p>Thyroid carcinoma, Twist expression, x100. A. Conventional PTC, high expression; B. Conventional PTC, low expression; C. Follicular PTC, low expression; D. Tall cell variant of PTC, high expression; E. Conventional FTC, high expression; F. Conventional FTC, low expression</p></caption><graphic xlink:href="CHSJ-40-3-184-fig1"/></fig><p>We found no differences in Twist expression depending on the type (p = 0.571, Fisher's Exact Test) or subtype of the tumor (p = 0.433, chi square test). Also, we found no statistical association of Twist immunoexpression in relation to gender and age groups of patients.</p><p>The high grade Twist expression was associated with cases of thyroid carcinomas that presented invasion of adjacent structures (p=0.002, chi square test, fig.<xref ref-type="fig" rid="F2">2</xref>A).</p><p>Also high grade Twist expression was associated with thyroid carcinomas that have associated lymph node metastases (p=0.01, chi square test, fig.<xref ref-type="fig" rid="F2">2</xref>B)</p><fig id="F2" orientation="portrait" position="float"><label>Fig.2</label><caption><p>Distribution of Twist positive cases in relation to the stage of tumors (A) and the presence of metastases (B)</p></caption><graphic xlink:href="CHSJ-40-3-184-fig2"/></fig></sec><sec sec-type="discussion"><title>Discussion</title><p>Twist is a member of the class of transcription factors, one of the molecules involved in the regulation of epithelial-mesenchymal transition (EMT) via regulation of key proteins that maintain the characteristics of epithelial cells and which that gives a mesenchymal phenotype [<xref rid="B10" ref-type="bibr">10</xref>]. Twist is overexpressed in many tumor types, including breast, gastric, hepatocellular, prostate [<xref rid="B11" ref-type="bibr">11</xref>], lung [<xref rid="B8" ref-type="bibr">8</xref>], esophagus [<xref rid="B12" ref-type="bibr">12</xref>] and bladder [<xref rid="B6" ref-type="bibr">6</xref>]. In some studies Twist overexpression is associated with high-grade cancer aggressiveness and poor patient survival rate [<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>].</p><p>Epithelial-mesenchymal transition (EMT) is a dedifferentiation program that converts epithelial cells into mesenchymal phenotype and is involved in cancer progression [15]. More recent studies have indicated that EMT also plays a critical role not only in tumor metastasis, but also in tumor recurrence, processes that are considered to be closely related to the biology of cancer stem-like cells or initiation cancer cells [<xref rid="B14" ref-type="bibr">14</xref>-<xref rid="B18" ref-type="bibr">18</xref>]. Twist is a transcription factor that promotes EMT associated with tumor metastasis, cancer stem cells and drug resistance [<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B20" ref-type="bibr">20</xref>].</p><p>Twist role in tumor progression is associated with the metastatic process [<xref rid="B10" ref-type="bibr">10</xref>]. Twist overexpression increases the invasive and metastatic ability of cancer cells by downregulation of E-cadherin expression and induction of EMT [<xref rid="B10" ref-type="bibr">10</xref>]. Twist plays an important role in some of the processes involved in the development of metastasis, such as angiogenesis, invasion and extravasation of chromosomal instability, and also protects cancer cells from apoptosis [<xref rid="B21" ref-type="bibr">21</xref>].</p><p>In our study we analyzed the Twist expression in 43 differentiated thyroid carcinomas. Both the variants of papillary and follicular thyroid carcinomas presented variable immunoreactions, with cases with low and high Twist expression with no statistically significant differences in relation to tumor type or subtype.</p><p>In a study conducted in 2013, Ni Wang et al. analyzed 121 papillary thyroid carcinomas and found low Twist expression in 56.6% of the cases, and high expression of the protein in 43.4% of the cases, without difference between tumor subtype, respectively, in conventional, follicular, tall cells and oncocitic variants; in the same study authors indicate non-significant differences of Twist expression in relation with pTNM stage, but a high protein expression in metastasing papillary carcinomas [<xref rid="B9" ref-type="bibr">9</xref>]. In our study, low Twist expression was present in 53.8% of PTC and high expression in 46.2% of these lesions, most commonly, but not statistically significant in tall cell variant. Also, 75% of FTC cases present low expression and in 25% of cases we observed a high expression of Twist protein.</p><p>Twist expression is differently reported in the literature studies. Thus, D Buehler et al. in a study that investigated the expression of Twist 1 in 27 follicular carcinomas and 28 papillary thyroid carcinomas, including tall cell and follicular variants found no reactions in all cases, the immunostaining being present only in anaplastic forms of tumors [<xref rid="B22" ref-type="bibr">22</xref>]. On the contrary, CN He et al. in 2008, on a lot of 50 papillary thyroid carcinomas indicate Twist positivity in all cases, the marker expression being associated tumor aggressiveness [<xref rid="B23" ref-type="bibr">23</xref>].</p><p>In our study we found differences of Twist expression in relation to tumor stage (stage I / II versus stage III / IV) and the presence of metastasis, the protein expression being significantly higher in invasive tumors and in cases of tumors that had metastasized. In this respect, the literature indicates Twist as a marker of tumor aggressiveness, and associated with forms of invasive and metastatic carcinomas, including thyroid tumors [<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B22" ref-type="bibr">22</xref>,<xref rid="B23" ref-type="bibr">23</xref>].</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>In differentiated thyroid carcinomas, Twist overexpression is associated with an invasive and metastatic immunophenotype. Identifying of high grade Twist expression in various forms of differentiated papillary thyroid carcinomas supports for a personalized therapeutic attitude to increase patient survival. </p></sec></body><back><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>DeLellis</surname><given-names>RA</given-names></name><name><surname>Lloyd</surname><given-names>RV</given-names></name><name><surname>Heitz</surname><given-names>PU</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name></person-group><chapter-title>Pathology and genetics of tumours of endocrine organs</chapter-title><source>World health organization, Classification of Tumours</source><year>2004</year><publisher-loc>Lyon</publisher-loc><publisher-name>IARC Press</publisher-name></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzaferri</surname><given-names>EL</given-names></name><name><surname>Jhiang</surname><given-names>SM</given-names></name></person-group><article-title>Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.</article-title><source>Am J Med</source><year>1994</year><volume>97</volume><fpage>418</fpage><lpage>428</lpage><pub-id pub-id-type="pmid">7977430</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hundahl</surname><given-names>SA</given-names></name><name><surname>Fleming</surname><given-names>ID</given-names></name><name><surname>Fremgen</surname><given-names>AM</given-names></name><name><surname>Menck</surname><given-names>HR</given-names></name></person-group><article-title>A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995</article-title><source>Cancer</source><year>1998</year><volume>83</volume><fpage>2638</fpage><lpage>2648</lpage><pub-id pub-id-type="pmid">9874472</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sobrinho-Sim&#x000f5;es</surname><given-names>M</given-names></name><name><surname>Eloy</surname><given-names>C</given-names></name><name><surname>Magalh&#x000e3;es</surname><given-names>J</given-names></name><name><surname>Lobo</surname><given-names>C</given-names></name><name><surname>Amaro</surname><given-names>T</given-names></name></person-group><article-title>Follicular thyroid carcinoma</article-title><source>Mod Pathol</source><year>2011</year><volume>24</volume><fpage>10</fpage><lpage>18</lpage></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hay</surname><given-names>ID</given-names></name><name><surname>Thompson</surname><given-names>GB</given-names></name><name><surname>Grant</surname><given-names>CS</given-names></name><name><surname>Bergstralh</surname><given-names>EJ</given-names></name><name><surname>Dvorak</surname><given-names>CE</given-names></name><name><surname>Gorman</surname><given-names>CA</given-names></name><name><surname>Maurer</surname><given-names>MS</given-names></name><name><surname>McIver</surname><given-names>B</given-names></name><name><surname>Mullan</surname><given-names>BP</given-names></name><name><surname>Oberg</surname><given-names>AL</given-names></name><name><surname>Powell</surname><given-names>CC</given-names></name><name><surname>van Heerden</surname><given-names>JA</given-names></name><name><surname>Goellner</surname><given-names>JR</given-names></name></person-group><article-title>Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients</article-title><source>World J Surg</source><year>2002</year><volume>26</volume><fpage>879</fpage><lpage>885</lpage><pub-id pub-id-type="pmid">12016468</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallerand</surname><given-names>H</given-names></name><name><surname>Robert</surname><given-names>G</given-names></name><name><surname>Pasticier</surname><given-names>G</given-names></name><name><surname>Ravaud</surname><given-names>A</given-names></name><name><surname>Ballanger</surname><given-names>P</given-names></name><name><surname>Reiter</surname><given-names>RE</given-names></name><name><surname>Ferri&#x000e8;re</surname><given-names>JM</given-names></name></person-group><article-title>The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers</article-title><source>Urol Oncol</source><year>2010</year><volume>28</volume><fpage>473</fpage><lpage>479</lpage><pub-id pub-id-type="pmid">19272800</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>GZ</given-names></name><name><surname>Chan</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>CD</given-names></name><name><surname>Wang</surname><given-names>LH</given-names></name></person-group><article-title>Twist transcriptionally upregulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><fpage>1979</fpage><lpage>1987</lpage><pub-id pub-id-type="pmid">17332325</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Dong</surname><given-names>W</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Mu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>J</given-names></name></person-group><article-title>A comparison of Twist and E-cadherin protein expression in primary non-small-cell lung carcinoma and corresponding metastases</article-title><source>Eur J Cardiothorac Surg</source><year>2011</year><volume>39</volume><fpage>1028</fpage><lpage>1032</lpage><pub-id pub-id-type="pmid">21376622</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Luo</surname><given-names>HJ</given-names></name><name><surname>Yin</surname><given-names>GB</given-names></name><name><surname>Dong</surname><given-names>CR</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>GG</given-names></name><name><surname>Liu</surname><given-names>ZM</given-names></name></person-group><article-title>Overexpression of HIF-2&#x003b1;, TWIST, and CXCR4 is associated with lymph node metastasis in papillary thyroid carcinoma</article-title><source>Clin Dev Immunol</source><year>2013</year><volume>2013</volume><pub-id pub-id-type="publisher-id">589423</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Mani</surname><given-names>SA</given-names></name><name><surname>Donaher</surname><given-names>JL</given-names></name><name><surname>Ramaswamy</surname><given-names>S</given-names></name><name><surname>Itzykson</surname><given-names>RA</given-names></name><name><surname>Come</surname><given-names>C</given-names></name><name><surname>Savagner</surname><given-names>P</given-names></name><name><surname>Gitelman</surname><given-names>I</given-names></name><name><surname>Richardson</surname><given-names>A</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><article-title>Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis</article-title><source>Cell</source><year>2004</year><volume>117</volume><fpage>927</fpage><lpage>939</lpage><pub-id pub-id-type="pmid">15210113</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuen</surname><given-names>HF</given-names></name><name><surname>Chua</surname><given-names>CW</given-names></name><name><surname>Chan</surname><given-names>YP</given-names></name><name><surname>Wong</surname><given-names>YC</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Chan</surname><given-names>KW</given-names></name></person-group><article-title>Significance of TWIST and E-cadherin expression in the metastatic progression of prostatic cancer</article-title><source>Histopathology</source><year>2007</year><volume>50</volume><fpage>648</fpage><lpage>658</lpage><pub-id pub-id-type="pmid">17394502</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>KW</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Sung</surname><given-names>CO</given-names></name><name><surname>Do</surname><given-names>IG</given-names></name><name><surname>Ko</surname><given-names>YH</given-names></name><name><surname>Um</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name></person-group><article-title>Twist1 is an independent prognostic factor of esophageal squamous cell carcinoma and associated with its epithelial-mesenchymal transition</article-title><source>Ann Surg Oncol</source><year>2012</year><volume>19</volume><fpage>326</fpage><lpage>335</lpage><pub-id pub-id-type="pmid">21732143</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>T</given-names></name><name><surname>Qin</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name></person-group><article-title>Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms</article-title><source>Cell Res</source><year>2012</year><volume>22</volume><fpage>90</fpage><lpage>106</lpage><pub-id pub-id-type="pmid">21876555</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mani</surname><given-names>SA</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Liao</surname><given-names>MJ</given-names></name><name><surname>Eaton</surname><given-names>EN</given-names></name><name><surname>Ayyanan</surname><given-names>A</given-names></name><name><surname>Zhou</surname><given-names>AY</given-names></name><name><surname>Brooks</surname><given-names>M</given-names></name><name><surname>Reinhard</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>CC</given-names></name><name><surname>Shipitsin</surname><given-names>M</given-names></name><name><surname>Campbell</surname><given-names>LL</given-names></name><name><surname>Polyak</surname><given-names>K</given-names></name><name><surname>Brisken</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><article-title>The epithelial-mesenchymal transition generates cells with properties of stem cells</article-title><source>Cell</source><year>2008</year><volume>133</volume><fpage>704</fpage><lpage>715</lpage><pub-id pub-id-type="pmid">18485877</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiery</surname><given-names>JP</given-names></name><name><surname>Sleeman</surname><given-names>JP</given-names></name></person-group><article-title>Complex networks orchestrate epithelial-mesenchymal transitions</article-title><source>Nat Rev Mol Cell Biol</source><year>2006</year><volume>7</volume><fpage>131</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">16493418</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raimondi</surname><given-names>C</given-names></name><name><surname>Gianni</surname><given-names>W</given-names></name><name><surname>Cortesi</surname><given-names>E</given-names></name><name><surname>Gazzaniga</surname><given-names>P</given-names></name></person-group><article-title>Cancer stem cells and epithelial-mesenchymal transition: revisiting minimal residual disease</article-title><source>Curr Cancer Drug Targets</source><year>2010</year><volume>10</volume><fpage>496</fpage><lpage>508</lpage><pub-id pub-id-type="pmid">20384575</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollier</surname><given-names>BG</given-names></name><name><surname>Evans</surname><given-names>K</given-names></name><name><surname>Mani</surname><given-names>SA</given-names></name></person-group><article-title>The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies</article-title><source>J Mammary Gland Biol Neoplasia</source><year>2009</year><volume>14</volume><fpage>29</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">19242781</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ansieau</surname><given-names>S</given-names></name><name><surname>Bastid</surname><given-names>J</given-names></name><name><surname>Doreau</surname><given-names>A</given-names></name><name><surname>Morel</surname><given-names>AP</given-names></name><name><surname>Bouchet</surname><given-names>BP</given-names></name><name><surname>Thomas</surname><given-names>C</given-names></name><name><surname>Fauvet</surname><given-names>F</given-names></name><name><surname>Puisieux</surname><given-names>I</given-names></name><name><surname>Doglioni</surname><given-names>C</given-names></name><name><surname>Piccinin</surname><given-names>S</given-names></name><name><surname>Maestro</surname><given-names>R</given-names></name><name><surname>Voeltzel</surname><given-names>T</given-names></name><name><surname>Selmi</surname><given-names>A</given-names></name><name><surname>Valsesia-Wittmann</surname><given-names>S</given-names></name><name><surname>Caron de Fromentel</surname><given-names>C</given-names></name><name><surname>Puisieux</surname><given-names>A</given-names></name></person-group><article-title>Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence</article-title><source>Cancer Cell</source><year>2008</year><volume>14</volume><fpage>79</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">18598946</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>TK</given-names></name><name><surname>Poon</surname><given-names>RT</given-names></name><name><surname>Yuen</surname><given-names>AP</given-names></name><name><surname>Ling</surname><given-names>MT</given-names></name><name><surname>Kwok</surname><given-names>WK</given-names></name><name><surname>Wang</surname><given-names>XH</given-names></name><name><surname>Wong</surname><given-names>YC</given-names></name><name><surname>Guan</surname><given-names>XY</given-names></name><name><surname>Man</surname><given-names>K</given-names></name><name><surname>Chau</surname><given-names>KL</given-names></name><name><surname>Fan</surname><given-names>ST</given-names></name></person-group><article-title>Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition</article-title><source>Clin Cancer Res</source><year>2006</year><volume>12</volume><fpage>5369</fpage><lpage>5376</lpage><pub-id pub-id-type="pmid">17000670</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vald&#x000e9;s-Mora</surname><given-names>F</given-names></name><name><surname>G&#x000f3;mez del Pulgar</surname><given-names>T</given-names></name><name><surname>Bandr&#x000e9;s</surname><given-names>E</given-names></name><name><surname>Cejas</surname><given-names>P</given-names></name><name><surname>Ram&#x000ed;rez</surname><given-names>de Molina A</given-names></name><name><surname>P&#x000e9;rez-Palacios</surname><given-names>R</given-names></name><name><surname>Gallego-Ortega</surname><given-names>D</given-names></name><name><surname>Garc&#x000ed;a-Cabezas</surname><given-names>MA</given-names></name><name><surname>Casado</surname><given-names>E</given-names></name><name><surname>Larrauri</surname><given-names>J</given-names></name><name><surname>Nistal</surname><given-names>M</given-names></name><name><surname>Gonz&#x000e1;lez-Bar&#x000f3;n</surname><given-names>M</given-names></name><name><surname>Garc&#x000ed;a-Foncillas</surname><given-names>J</given-names></name><name><surname>Lacal</surname><given-names>JC</given-names></name></person-group><article-title>TWIST1 overexpression is associated with nodal invasion and male sex in primary colorectal cancer</article-title><source>Ann Surg Oncol</source><year>2009</year><volume>16</volume><fpage>78</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">19002529</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>MA</given-names></name><name><surname>Chen</surname><given-names>HC</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name></person-group><article-title>Twist: a molecular target in cancer therapeutics</article-title><source>Tumour Biol</source><year>2013</year><volume>34</volume><fpage>2497</fpage><lpage>2506</lpage><pub-id pub-id-type="pmid">23873099</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buehler</surname><given-names>D</given-names></name><name><surname>Hardin</surname><given-names>H</given-names></name><name><surname>Shan</surname><given-names>W</given-names></name><name><surname>Montemayor-Garcia</surname><given-names>C</given-names></name><name><surname>Rush</surname><given-names>PS</given-names></name><name><surname>Asioli</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Lloyd</surname><given-names>RV</given-names></name></person-group><article-title>Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas</article-title><source>Mod Pathol</source><year>2013</year><volume>26</volume><fpage>54</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">22899291</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>CN</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Cheng</surname><given-names>JQ</given-names></name><name><surname>Chen</surname><given-names>SC</given-names></name><name><surname>Zhao</surname><given-names>HF</given-names></name><name><surname>Zhai</surname><given-names>JP</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name></person-group><article-title>Expression of Twist in papillary thyroid carcinomas and its roles in differential diagnosis</article-title><source>Zhonghua Bing Li Xue Za Zhi</source><year>2008</year><volume>37</volume><issue>1</issue><fpage>35</fpage><lpage>39</lpage><comment>Full article in Chinese</comment><pub-id pub-id-type="pmid">18509983</pub-id></element-citation></ref></ref-list></back></article>